atoltivimab, maftivimab, and odesivimab-ebgn drug combination

Also Known As:

Inmazeb; R3470-3471-3479; REGN EB3; REGN-3470-3471-3479; REGN-EB3; REGN3470-3471-3479; REGNEB3; atoltivimab, maftivimab, and odesivimab drug combination; atoltivimab, maftivimab, odesivimab

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Collaborators: 1 article (09/2022)
2.	Fowler, Robert: 1 article (09/2022)
3.	Gao, Ya: 1 article (09/2022)
4.	Ge, Long: 1 article (09/2022)
5.	Guyatt, Gordon: 1 article (09/2022)
6.	Hao, Qiukui: 1 article (09/2022)
7.	Kojan, Richard: 1 article (09/2022)
8.	Tian, Jinhui: 1 article (09/2022)
9.	Zhao, Yunli: 1 article (09/2022)
10.	Gong, Rui: 1 article (12/2021)

Related Diseases

1.	Infections 01/01/2021 - "This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients." 12/01/2021 - "Now two antibody drugs termed Inmazeb and Ebanga have been approved for treating EBOV infection. " 09/08/2022 - "Filovirus-specific monoclonal antibodies (mAbs) confer protection in nonhuman primates as late as 5 days after challenge, and FDA-approved mAbs REGN-EB3 and mAb114 have demonstrated efficacy against Ebola virus (EBOV) infection in humans. " 08/01/2021 - "Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus."
2.	Ebola Hemorrhagic Fever 01/01/2021 - "Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. " 01/01/2022 - "These findings suggest that health-care workers should prioritise the use of REGN-EB3 and mAb114 for patients with Ebola virus disease during future outbreaks. " 08/01/2021 - "Atoltivimab/ maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved treatment for Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who is reverse transcription polymerase chain reaction (RT-PCR)-positive for Zaire ebolavirus infection. " 11/30/2023 - "Antibody concentrations were measured by the multiplex immunoassay, and the association between anti-Ebola virus antibody levels and the relevant exposures, such as anti-Ebola virus disease drugs (ansuvimab, REGN-EB3, ZMapp, or remdesivir), was assessed using both linear and logistic mixed regression models. " 10/01/2022 - "REGN-EB3 (Inmazeb) is a cocktail of three human monoclonal antibodies approved for treatment of Ebola infection. "

Related Drugs and Biologics

1.	ansuvimab
2.	Monoclonal Antibodies
3.	atoltivimab, maftivimab, and odesivimab-ebgn drug combination
4.	remdesivir
5.	ZMapp